Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.

Arman Ali Ghodsinia,Reynaldo L Garcia,J-Ann Marie T Lego

doi:10.3390/cells9051116

Arman Ali Ghodsinia, Reynaldo L Garcia + Show 1 more

Open Access

https://doi.org/10.3390/cells9051116

Copy DOI

Journal: Cells	Publication Date: Apr 30, 2020
Citations: 6	License type: CC BY 4.0

Affiliation: University of the Philippines Diliman

Abstract

Phosphatidylinositol 3-kinase, catalytic subunit alpha (PIK3CA) is an oncogene often mutated in colorectal cancer (CRC). The contribution of PIK3CA mutations in acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy is well documented, but their prognostic and predictive value remain unclear. Domain- and exon-specific mutations are implicated in either favorable or poor prognoses, but there is paucity in the number of mutations characterized outside of the mutational hotspots. Here, two novel non-hotspot mutants—Q661K in exon 13 and C901R in exon 19—were characterized alongside the canonical exon 9 E545K and exon 20 H1047R mutants in NIH3T3 and HCT116 cells. Q661K and E545K both map to the helical domain, whereas C901R and H1047R map to the kinase domain. Results showed variable effects of Q661K and C901R on morphology, cellular proliferation, apoptosis resistance, and cytoskeletal reorganization, with both not having any effect on cellular migration. In comparison, E545K markedly promoted proliferation, survival, cytoskeletal reorganization, migration, and spheroid formation, whereas H1047R only enhanced the first three. In silico docking suggested these mutations negatively affect binding of the p85 alpha regulatory subunit to PIK3CA, thereby relieving PIK3CA inhibition. Altogether, these findings support intra-domain and mutation-specific variability in oncogenic readouts, with implications in degree of aggressiveness.

Highlights

Phosphatidylinositol 3-kinase, catalytic subunit alpha (PIK3CA) is an oncogene mutated in10% to 25% of colorectal cancers (CRCs) [1,2,3,4]
Given the myriad of signaling pathways affected by PIK3CA, which include both AKT-dependent and -independent mechanisms [22,23,24,25,26], there is a need to phenotypically characterize the oncogenic readouts of non-hotspot mutations in more cancer hallmarks
This study reports the phenotypic characterization of two novel non-hotspot PIK3CA mutations, namely, Q661K (NM_006218.1: c.1981C > A) located in exon 13 and C901R (Pfam entry PF00454)

Summary

Introduction

Phosphatidylinositol 3-kinase, catalytic subunit alpha (PIK3CA) is an oncogene mutated in10% to 25% of colorectal cancers (CRCs) [1,2,3,4]. Phosphatidylinositol 3-kinase, catalytic subunit alpha (PIK3CA) is an oncogene mutated in. Hotspot mutations in PIK3CA lie in exon 9 (E542K and E545K) in the helical domain and exon 20 (H1047R) in the catalytic kinase domain. These mutations may co-exist with Kirsten Rat Sarcoma Viral Oncogene. Homolog (KRAS) and B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) mutations to exert different oncogenic effects and responses to anti-EGFR therapy [5]. Studies have correlated exon 20 mutations but not exon 9 mutations to poor response to anti-EGFR therapy in metastatic colorectal cancer [2,7,8].

Methods

Results

Conclusion